Goldman Says “Good Opportunity To Buy Dip” In Obesity Drug Stocks Novo Nordisk shares in Europe appear to be forming a base after a 5.5-month bottoming process, following a mid-2024 peak and a subsequent 71% collapse. Goldman analyst Faris Mourad is telling clients this week that “obesity drugs narrative sentiment is on the rise” and “it’s an opportunity to buy the dip.” Mourad explained: The relative performance of the Obesity Drugs basket (GSHLCBMI) to the S&P 500 (SPX) is lagging its narrative sentiment. The basket is down -2 standard deviations today and we think it’s a good opportunity to buy… — Continue at ZeroHedge News : Read More
